An integromic signature for lung cancer early detection
Metrics: PDF 721 views | HTML 985 views | ?
Qixin Leng1,*, Yanli Lin1,*, Min Zhan2 and Feng Jiang1
1Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
2Department of Epidemiology & Public Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA
*These authors have contributed equally to this work
Feng Jiang, email: firstname.lastname@example.org
Keywords: diagnosis; early stage; lung cancer; plasma; biomarkers
Received: March 24, 2018 Accepted: April 07, 2018 Published: May 15, 2018
We previously developed three microRNAs (miRs-21, 210, and 486-5p), two long noncoding RNAs (lncRNAs) (SNHG1 and RMRP), and two fucosyltransferase (FUT) genes (FUT8 and POFUT1) as potential plasma biomarkers for lung cancer. However, the diagnostic performance of the individual panels is not sufficient to be used in the clinics. Given the heterogeneity of lung tumors developed from multifactorial molecular aberrations, we determine whether integrating the different classes of molecular biomarkers can improve diagnosis of lung cancer. By using droplet digital PCR, we analyze expression of the seven genes in plasma of a development cohort of 64 lung cancer patients and 33 cancer-free individuals. The panels of three miRNAs (miRs-21, 210, and 486-5p), two lncRNAs (SNHG1 and RMRP), and two FUTs (FUT8 and POFUT1) have a sensitivity of 81-86% and a specificity of 84-87% for diagnosis of lung cancer. From the seven genes, an integromic plasma signature comprising miR-210, SNHG1, and FUT8 is developed that produces higher sensitivity (95.45%) and specificity (96.97%) compared with the individual biomarker panels (all p<0.05). The diagnostic value of the signature was confirmed in a validation cohort of 40 lung cancer patients and 29 controls, independent of stage and histological type of lung tumor, and patients’ age, sex, and smoking status (all p>0.05). The integration of the different categories of biomarkers might improve diagnosis of lung cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.